Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4′-dimethoxy-3′-amino-Z-stilbene and derived amino acid amides

Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2003, Pages 525-531

  Pettit, George R ^a   Anderson, Collin R ^a   Herald, Delbert L ^a   Katherine Jung, M ^b   Lee, Debbie J ^c   Hamel, Ernest ^c   Pettit, Robin K ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXY 5,4' DIMETHOXY 3' NITROSTILBENE DERIVATIVE; ANTINEOPLASTIC AGENT; COLCHICINE; PHOSPHONIUM DERIVATIVE; STILBENE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; ISOMERISM; MITOSIS INDEX; NONHUMAN; REACTION ANALYSIS; REDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

AMIDES; AMINO ACIDS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BIOPOLYMERS; DIOXOLES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MITOSIS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0037434583     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020204l     Document Type: Article

References (26)

1. Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. 1988, 34, 200-208.
2. Lin, C. M.; Ho, H. H.; Pettit, G. R. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28, 6984-6991.
3. Pettit, G. R.; Singh, S. B. Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2. Can. J. Chem. 1987, 65, 2390-2396.
4. Pettit, G. R.; Temple, C., Jr.; Narayanan, V. L.; Varma, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Des. 1995, 10, 299-309.
5. Pettit, G. R.; Rhodes, M. R. Antineoplastic agents 389. New Synthesis of combretastatin A-4 prodrug. Anti-Cancer Drug Des. 1998, 13, 183-191.
6. Galbraith, S. M.; Chaplin, D. J.; Lee, F.; Stratford, M. R. I.; Locke, R. J.; Vojnovic, B.; Tozer, G. M. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001, 21, 93-102.
7. Boehle, A. S.; Sipos, B.; Kliche, U.; Kalthoff, H.; Dohrmann, P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann. Thorac. Surg. 2001, 71, 1657-1665.
8. Remick, S. C.; Dowlati, A.; Robertson, K.; Spiro, T.; Connell, C.; Levitan, N.; Stratford, M. Phase I pharmacokinetics study of single dose intravenous (IV) combretastatin A-4 prodrug (CA4P) in patients (pts) with advanced cancer. In Molecular Targets and Cancer Therapeutics Discovery, Development, and Clinical Validation, Proceedings of the AACR-NCI-EORTC International Congress, Washington, DC, 1999; No. 16, p 4.
9. Rustin, G. J. S.; Galtraith, S. M.; Taylor, N. J.; Maxwell, R.; Tozer, G.; Baddeley, H.; Wilson, I.; Prose, V. Combretastatin A-4 phosphate (CA4P) selectively targets vasculature in animal and human tumors. In Molecular Targets and Cancer Therapeutics Discovery, Development, and Clinical Validation, Proceedings of the AACR-NCI-EORTC International Congress, Washington, DC, 1999; No.14, p 4.
10. Griggs, J.; Metcalfe, J. C.; Hesketh, R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol. 2001, 2, 82-87.
11. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209-211.
12. Gwaltney, S. L., II; Imade, H. M.; Barr, K. J.; Qun, L.; Gehrke, L.; Credo, R. B.; Warner, R. B.; Lee, J. Y.; Kovar, P.; Wang, J.; Nukkala, M. A.; Zielinski, N. A.; Frost, D.; Ng, S.; Sham, H. L. Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg. Med. Chem. Lett. 2001, 11, 871-874.
13. Maya, A.; Del Rey, B.; DeClairac, R. P.; Caballero, E.; Borasoain, I.; Andreu, J. M.; Medarde, M. Design, synthesis and cytotoxic activities of naphthyl analogs of combretastatin A-4. Bioorg. Med. Chem. Lett. 2000, 10, 2549-2551.
14. Pinney, K. G.; Mejia, M. P.; Villalobos, V. M.; Rosenquist, B. E.; Pettit, G. R.; Verdier-Pinard, P.; Hamel, E. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg. Med. Chem. 2000, 8, 2417-2425.
15. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Toshihiro, H.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem. 1998, 41, 3022-3032.
16. Ohsumi, K.; Hatanaka, R.; Nakagawa, R.; Fukuda, Y.; Morinaga, Y.; Suga, Y.; Nihei, Y.; Ohishi, K.; Akiuama, Y.; Tsuji, T. Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anti-Cancer Drug Des. 1999, 14, 539-548.
17. Grimaudo, S.; Tolomeo, M.; Capone, F.; Pagliaro, M.; Rodanin, R.; Baruchello, R.; Simoni, D.; Mariani, G. Effects of AC7739, a water-soluble amino derivative of combretastatin A-4, in multidrug-resistant and apoptosis-resistant leukemia cell lines. Blood 2001, 98, 445.
18. Ohno, T.; Kawano, K.; Tahara, K.; Aramaki, M.; Sasaki, A.; Takeuchi, Y.; Kai, S.; Ishio, T.; Kitano, S. Antitumor effect of combretastatin A-4 derivative, AC7700, against rat liver cancer. Gastroenterology 2001, 120, 2831.
19. Waldeck, D. H. Photoisomerization dynamics of stilbenes. Chem. Rev. 1991, 91, 415-436.
20. Coste, J.; Frerot, E.; Jouin, P.; Castro, B. Oxybenzotriazole free peptide coupling reagents for N-methylated amino acids. Tetrahedron Lett. 1991, 32, 1967-1970.
21. Carpino, L. A.; Sadat-Aalaee, D.; Beyermann, M. Tris(2-aminoethyl)amine as a substitute for 4-(aminomethyl)piperidine in the FMOC/polyamine approach to rapid peptide synthesis. J. Org. Chem. 1990, 55, 1673-1675.
22. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4; NCCLS: Wayne, PA, 1997.
23. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A; NCCLS: Wayne, PA, 1997.
24. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol. Pharmacol. 1998, 53, 62-76.
25. SHELXTL-NT, version 5.10 (1997), an integrated suite of programs for the determination of crystal structures from diffraction data, is available from Bruker AXS, Inc., Madison, WI 53719. This package includes, among others, XPREP (an automatic space group determination program), SHELXS (a structure solution program via Patterson or direct methods), and SHELXL (structure refinement software).
26. Blessing, R. H. An Empirical Corrrection for Absorption Anisotropy. Acta Crystallogr. 1995, A51, 33-38.